FDA Acceptance of Zevra ' s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA, the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration's (FDA) acceptance of Zevra Therapeutics' New Drug Application (NDA) for arimoclomol, an orally-delivered,…#emeryville #xomacorporationxoma #fda #nda #npc #xoma #ladrx #arimoclomol #bradsitko #zevra
Source: Reuters: Health - Category: Consumer Health News Source Type: news